The company announced that it would begin US trials in July and would conduct these trials alongside the National Institute of Allergy and Infectious Diseases (NIAID). It will include 30,000 participants, randomised and placebo controlled. Based on results from Phase I study, the 100 μg dose level was chosen as the optimal dosage, allowing for the maximum immune response whilst minimizing adverse reactions. Moderna says it can deliver approximately 500 million doses per year. Through a strategic collaboration with Lonza, Moderna will be able to manufacture up to 1 billion doses per year and they plan to start manufacturing even before the vaccine's efficacy is established, in an effort to get ahead of the competition.
Messenger RNA: Genetic instructions for the coronavirus spike protein are encoded in mRNA, delivered via lipid nanoparticle.
With Lonza, 1 billion doses per year.
Up to $483 million.
mRNA-1273 is an mRNA vaccine against SARS-CoV-2 encoding for a stabilised form of the Spike (S) protein, which was selected by Moderna in collaboration with investigators from Vaccine Research Center (VRC) at the National Institute of Allergy and Infectious Diseases (NIAID), a part of the NIH.
The potential advantages of an mRNA approach to prophylactic vaccines include the ability to combine multiple mRNAs into a single vaccine, rapid discovery to respond to emerging pandemic threats and manufacturing agility derived from the platform nature of mRNA vaccine design and production.